版本:
中国

BRIEF-Exelixis announces positive results from phase 2 trial of Cabozantinib vs Sunitinib

Oct 10 Exelixis Inc :

* Exelixis announces positive results from phase 2 cabosun trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma presented at esmo 2016

* Abozantinib met primary endpoint of improving progression-free survival as compared to sunitinib

* Based on these results, exelixis plans to submit a supplemental new drug application (snda) for cabozantinib Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐